$76.57−0.02 (−0.03%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Disc Medicine (IRON) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+58.2%) and Capex step-up ($933.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼94.0%
−212.2
FY21→FY25CAGR —
Free cash flow ($M)▼92.0%
−181.3
capex stepped upCAGR —
Diluted EPS▼51.8%
−6.01
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+58.2%
22.3mn → 35.3mn diluted shares since FY23. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$933.0K
▲85% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 183,141.0 | 170,640.0 | 96,671.0 | 69,264.0 | 33,437.0 | 25,170.0 | ▲76.5% | +61.4% |
Selling, general & admin | 82,589.0 | 65,382.0 | 33,049.0 | 21,861.0 | 14,038.0 | 5,763.0 | ▲97.8% | +83.5% |
Total operating expenses | 265,730.0 | 236,022.0 | 129,720.0 | 91,125.0 | 47,475.0 | 30,933.0 | ▲81.9% | +66.2% |
Operating incomefeeds ROC rank | −265,730.0 | −236,022.0 | −129,720.0 | −91,125.0 | −47,475.0 | −30,933.0 | ▼81.9% | — |
Other income, net | 22,945.0 | 24,199.0 | 20,718.0 | 14,795.0 | 648.0 | −5,036.0 | — | — |
Pretax income | −242,785.0 | −211,823.0 | −109,002.0 | −76,330.0 | −46,827.0 | −35,969.0 | ▼94.3% | — |
Income tax | 317.0 | 361.0 | 355.0 | 99.0 | 0.0 | — | ▲1.7% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −243,102.0 | −212,184.0 | −109,357.0 | −76,429.0 | −46,827.0 | −35,969.0 | ▼94.0% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −6.36 | −6.01 | −3.96 | −3.42 | −45.05 | −40.95 | ▼51.8% | — |
Diluted shares (mn) | 38.90 | 35.30 | 27.61 | 22.32 | 1.04 | 0.88 | ▲27.9% | +151.8% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

